Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.

You may also be interested in...



Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence

The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.

Ironwood Eyes Large Market For Linaclotide, Will Tread Carefully On Price

Ironwood Pharmaceuticals Inc. is confident about the large market potential for its constipation drug linaclotide, but as the market now is dominated by over-the-counter laxatives, it knows it has to be "smart" when it comes to price in order to win over payers.

Ironwood Pharmaceuticals: Independent for the Long Haul

Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC081688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel